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Abstract
Background: Stochastic resonance therapy (SRT) is used for rehabilitation of patients with various neuropsychiatric diseases. An 
alteration in tryptophan metabolism along the kynurenine pathway has been identified in the central and peripheral nervous systems in 
patients with neuroinflammatory and neurodegenerative diseases and during the aging process. This study investigated the effect of SRT 
as an exercise activity on serum tryptophan metabolites in healthy subjects.
Methods: Serum L-tryptophan, L-kynurenine, kynurenic acid, and anthranilic acid levels were measured one minute before SRT and at 
one, 5, 15, 30, and 60 minutes after SRT. We found that SRT affected tryptophan metabolism. Serum levels of L-tryptophan, L-kynurenine, 
and kynurenic acid were significantly reduced for up to 60 minutes after SRT. Anthranilic acid levels were characterized by a moderate, 
non significant transient decrease for up to 15 minutes, followed by normalization at 60 minutes. Tryptophan metabolite ratios were 
moderately altered, suggesting activation of metabolism after SRT. Lowering of tryptophan would generally involve activation of 
tryptophan catabolism and neurotransmitter, protein, and bone biosynthesis. Lowering of kynurenic acid by SRT might be relevant for 
improving symptoms in patients with neuropsychiatric disorders, such as Parkinson’s disease, Alzheimer’s disease, schizophrenia, and 
depression, as well as certain pain conditions.
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Introduction
A phenomenon called stochastic resonance, in which 
vibration increases the response of a nonlinear   system 
to a weak signal, may influence molecular biological 
machinery  and  physiological  responses.  The  first 
report  on  the  mechanism  of  stochastic  resonance 
was published by Benzi et al,1 and its significance 
was used as a theoretical explanation for the periodic 
recurrences  of  Earth’s  ice  ages.2,3  Interestingly,  in 
biology, stochastic resonance has been demonstrated 
experimentally  in  various  sensorineural  systems, 
including  the  crayfish,4  shark,5  cricket,6  and  also 
in humans.7,8 Collins et al7 showed that the tactile 
sensation of the human fingertip can be enhanced by 
mechanical vibration, and the findings reported by 
Collins et al8 suggest that mechanoreceptors can be 
influenced by stochastic resonance. Tanaka et al9 have 
shown that low-amplitude, broad-frequency vibration 
increases the expression of osteocalcin mRNA, and 
suggested that stochastic resonance might enhance 
mechanosensation in bone tissue. In an in vivo animal 
study,  Tanaka  et  al10  showed  that  low-amplitude, 
broad-frequency vibration combined with simulated 
exercise enhanced new bone formation, and suggested 
a potential role of exercise in elderly people as well 
as after injury to build up bone mass and help prevent 
osteoporosis. Generally, walking and running might 
influence  the  elementary  functions  of  the  central 
nervous system. In an animal experiment, a strong 
positive  correlation  was  found  between  running 
distance  and  release  of  brain-derived  neurotrophic 
factor,11  running  distance  and  increased  release  of 
nerve  growth  factor,12  and  running  exercise  and 
increasing  cell  proliferation  and  neurogenesis  in 
the  hippocampal  area.13  Kepplinger  et  al14  showed 
that  treadmill  running  significantly  lowered  serum 
kynurenic acid levels in the rat, while Alaei et al15 
demonstrated that treadmill running enhanced mid-
term memory. In this regard it is important to note that 
kynurenic acid may interfere with working memory,16 
and  enhancement  of  endogenous  kynurenic  acid 
levels may induce spatial memory deficits.17
Central and peripheral tissues are actively involved 
in tryptophan metabolism, including in synthesis of 
serotonin, and along the kynurenine pathway, where 
it can form several neuroactive compounds.18,19 One 
of them, kynurenic acid, is a well known endogenous 
antagonist of glutamate ionotropic excitatory amino 
acid receptors,20,21 and a nicotine cholinergic subtype 
alpha-7 receptor22,23 is altered significantly in patients 
with  various  neuropsychiatric  and  immunological 
  disorders  and  in  the  aging  process.24–28  Notably, 
enhancement of kynurenic acid in the central nervous 
system has been suggested to contribute to impairment 
of memory and cognition.29,30 Furthermore, we have 
suggested  that  rehabilitation  strategies  leading  to 
kynurenic acid reduction might have a therapeutic 
role,31 at least in conditions involving elevation of 
kynurenic acid.
The aim of this study was to determine if SRT can 
affect  tryptophan  metabolism  in  the  human  body. 
L-tryptophan,  L-kynurenine,  kynurenic  acid,  and 
anthranilic acid levels were measured in the serum of 
healthy subjects one minute before and one, 15, 30, 
and 60 minutes after SRT. Some of the data from this 
study have already been published in abstract form.32
Materials and Methods
chemicals
L-tryptophan, L-kynurenine, kynurenic acid, anthra-
nilic  acid,  3-OH-kynurenine,  and  3-OH-anthranilic 
acid was purchased from Sigma (St. Louis, MO). All 
other chemicals used were of the highest commer-
cially available purity.
Subjects
Ten  non-smoking  volunteers,  comprising  two  men 
and eight women, aged 33.2 ± 4.1 years, participated 
in this study. SRT was applied in all cases between 
11 am and noon. All subjects had breakfast as usual 
before 7.30 am. In order to minimize stress, all sub-
jects underwent insertion of a mini cannula (butter-
fly needle) before SRT. Blood was taken one minute 
before SRT and at one, 5, 15, 30 and 60 minutes after 
SRT. The serum obtained was subjected to centrifu-
gation for five minutes at 3000 rpm, and was stored 
at −40 °C until analysis. Blood samples were also 
taken from a further three subjects who did not receive 
SRT, in order to demonstrate a lack of effect on tryp-
tophan metabolites due to blood collection. Samples 
of serum were coded and the study was carried out 
according to lower Austrian ethical regulations.
Methods
The SRT-Medical Zeptoring™ system (GmbH and 
Co Lifescience, KG Berlin, Germany), a training and Stochastic resonance and tryptophan metabolism
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medical therapy device with stochastic vibration up 
to 12 levels was used. Volunteers were exposed to 
five two-minute exercise periods at the level of 10 on 
the SRT-Medical Zeptoring system, with a 30-second 
interval between each 2-minute exercise period.
Measurement of tryptophan  
and tryptophan metabolites
Briefly, 200 µL samples of serum were mixed with 
14 µL of 50% trichloroacetic acid and 0.2 M HCl (v/v), 
and centrifuged for 20 minutes at 14,000 rpm. The 
supernatant obtained was divided and immediately 
used for measurement of tryptophan and tryptophan 
metabolites, and for purification of kynurenic acid 
followed by determination.
Tryptophan,  L-kynurenine,  3-OH-kynurenine, 
anthranilic  acid,  and  3-OH-anthranilic  acid  were 
measured  by  isocratic  high-performance  liquid 
chromatography  (HPLC)  with  fluorescence  and 
ultraviolet  detection  as  described  by  Baran  et  al, 
with some modifications.31 Briefly, the HPLC system 
consisted of a Merck Hitachi LaChrom Pump L-7100, 
autosampler  L-7200,  fluorescence  detector  L7485, 
ultraviolet  detector  L-7400,  and  a  Merck  Hitachi 
D-7500  integrator.  The  HPLC  method  utilized  a 
mobile phase of 42 mM ammonium acetate, 7 mM 
sodium hydrogen phosphate, 7 mM sodium acetate, 
11 mM ammonium hydroxide, 59 mM acetic acid, 
1.380 mM 1-octanesulfonic acid, and 74 µM sodium 
disulfide (pH 4.8) pumped through a ChromolithTM 
Performance RP-18e, 100-4, 6 mm column (Merck 
KGaA,  Darmstadt,  Germany)  at  a  flow  rate  of 
0.7 mL/minutes. The injection volume was 50 µL. 
The  fluorescence  detector  was  set  at  an  excitation 
wavelength of 299 nm and an emission wavelength of 
420 nm. The retention time of 3-OH-anthranilic acid, 
anthranilic acid, and tryptophan was approximately 
7.4,  15.6,  and  17.7  minutes,  respectively,  with  a 
sensitivity  of  80,  800  and  150  fmol  per  injection, 
respectively  (signal:noise  ratio  5).  Using  the  same 
HPLC  conditions  and  an  ultraviolet  detector  set 
at  a  366  nm  wavelength,  3-OH-kynurenine  and 
L-kynurenine were eluted, with a retention time of 4.3 
and 7.7 minutes and a sensitivity of 700 and 500 fmol 
per injection, respectively (signal:noise ratio 5).
Measurement  of  kynurenic  acid  was  performed 
according to the method described by Swartz et al,33 
with  modifications  as  described  by  Baran  et  al.30 
Briefly, the serum samples were mixed with 0.2 M HCl 
(v/v) and centrifuged for 20 minutes at 14,000 rpm. 
The supernatant obtained was applied to a Dowex 
50 W cation exchange column prewashed with 0.1 
M HCl. The column was then washed with 1 mL 
0.1 M HCl and 1 mL distilled water, and kynurenic 
acid  was  eluted  with  2  mL  distilled  water34  and 
  quantitated using an HPLC system coupled with fluo-
rescence detection. The recovery of kynurenic acid 
  extraction  was  approximately  40%  and  was  taken 
into consideration in the data processing.
Data analysis
All data are presented as the mean ± standard error of 
the mean. For statistical analyses, one-way analysis 
of variance and a Student’s t-test were applied. Each 
sample  was  determined  in  duplicate  or  triplicate. 
*P , 0.05, **P , 0.01, and ***P , 0.001 indicate 
a  significant  difference  compared  with  baseline 
(15 minutes before administration of SRT).
Results
Serum tryptophan metabolites  
in controls
Control data for the serum tryptophan metabolites were 
comparable with those from other human studies.50 
Determination of tryptophan metabolites in the serum 
of human control subjects (n = 10) revealed the follow-
ing concentrations: L-tryptophan 74,682.0 ± 4581.0 
fmol/µL, L-kynurenine 3331.90 ± 240.93 fmol/µL, 
kynurenic acid 75.49 ± 4.95 fmol/µL, and anthranilic 
acid  30.74  ±  3.41  fmol/µL.  3-OH-kynurenine  and 
3-OH-anthranilic acid were not detectable in serum in 
this study. In subjects who were not exposed to SRT, 
no differences in tryptophan metabolite levels were 
seen during the different periods after blood collec-
tion. After SRT, all control subjects reported feeling 
well during and at two hours following exercise.
Influence of SRT on tryptophan 
metabolites
Application  of  SRT  significantly  affected  trypto-
phan  metabolism  in  serum.  We  found  moderately 
lowered  L-tryptophan  levels  at  one  minute  after 
SRT;  this  reduction  progressed  significantly  and 
was present at one hour after SRT (13%; P , 0.01, 
Fig. 1). Significant differences in serum L-tryptophan Kepplinger et al
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levels after SRT for the different time points were 
demonstrated  (F  =  2.4646,  P  =  0.0367,  one-way 
analysis of variance, Fig. 1).
L-kynurenine  levels  were  moderately  lower 
5 minutes after SRT, and this effect lasted until one 
hour after SRT (11%, P , 0.01, Fig. 2). No changes in 
serum L-kynurenine levels could be shown after SRT 
for the different time points (F = 0.7739, P = 0.5706, 
one-way analysis of variance, Fig. 2).
Anthranilic acid levels were moderately decreased 
at 5 and 15 minutes after SRT, and were normalized at 
one hour (Fig. 3). No differences in serum anthranilic 
acid levels were detected at the different time points 
after SRT (F = 0.6033, P = 0.6975, one-way analysis 
of variance, Fig. 3).
Kynurenic acid levels decreased at 5 minutes after 
SRT, and this reduction was still seen at one hour after 
SRT (20%, P , 0.001, Fig. 4). Differences in serum 
kynurenic acid levels after SRT for the different time 
points were demonstrated (F = 2.1910, P = 0.0601), 
one-way analysis of variance, Fig. 4).
The ratio of L-kynurenine to tryptophan did not 
change significantly at any of the time points after 
SRT for up to one hour (F = 0.2906, P = 0.9173, 
one-way analysis of variance, Fig. 5). The ratio of 
anthranilic  acid  to  L-kynurenine  was  moderately 
increased at 30 minutes and showed a tendency to 
increase at 60 minutes (about 23%, P , 0.05) after 
SRT (Fig. 6). No change in the anthranilic acid:L-
kynurenine  ratio  was  found  at  the  different  time 
points after SRT (F = 0.5689, P = 0.7237, one-way 
analysis of variance, Fig. 6). The ratio of kynurenic 
acid  to  L-kynurenine  showed  a  sinusoidal  but  not 
significant pattern of change up to 60 minutes after 
SRT (Fig. 7). No change in the ratio of kynurenic 
acid to L-kynurenine was found at any of the time 
points after SRT (F = 0.5857, P = 0.7176, one-way 
analysis of variance, Fig. 7). The ratio of kynurenic 
acid to anthranilic acid showed a moderate increase 
at 15 minutes and a decrease at 30 and 60 minutes 
(about 39% versus 15 minutes, P , 0.05, Fig. 8), but 
no change in the ratio of kynurenic acid to anthranilic 
acid was seen at any time point after SRT (F = 1.0341, 
P = 0.4012, one-way analysis of variance, Fig. 8).
Discussion
SRT  is  used  in  the  treatment  and  rehabilita-
tion  of  patients  with  various  neurological  and 
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Figure 1. Serum L-tryptophan levels at various time points after stochastic resonance therapy. 
notes: Data represent the mean ± standard error of the mean of 20 independent measurements. *P , 0.05; **P , 0.01; ***P , 0.001 compared with 
time before stochastic resonance therapy. a,b; b,c; b,d; d,e; and e,f indicate statistical significance at P , 0.05. a,d and c,e indicate statistical significance 
at P , 0.01. a,c; a,d; a,e; and b,f indicate statistical significance at P , 0.001. Analysis of variance: F = 2.4646; P = 0.0369. 
Abbreviation: TRP, L-tryptophan.Stochastic resonance and tryptophan metabolism
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Figure 2. Serum L-kynurenine levels at various time points after stochastic resonance therapy. 
notes: Data represent the mean ± standard error of the mean of 20 independent measurements. *P , 0.05; **P , 0.01; ***P , 0.001 compared with 
time before stochastic resonance therapy. b,d; b,e; and b,f indicate statistical significance at P , 0.05. a,d; a,f; and b,c indicate statistical significance 
at P , 0.01. a,c and a,e indicate statistical significance at P , 0.001. By analysis of variance, F = 0.7739; P = 0.5706.
Abbreviation: L-KYn, L-kynurenine.
0.00
10.00
20.00
30.00
40.00
50.00
60.00
70.00
80.00
Time (minutes)
A
N
A
 
(
p
m
o
l
/
m
L
)
a
bc
de
Zeptoring
−15 −10 −5 05 10 15 20 25 30 35 40 45 50 55 60
Figure 3. Serum anthranilic acid levels at various time points after stochastic resonance therapy. 
notes: Data shown are the mean ± standard error of the mean of 20 independent experiments. a, b indicates statistical significance at P , 0.05. 
c,d indicates statistical significance at P , 0.01. a,c and c,e indicate statistical significance at P , 0.001. By analysis of variance, F = 0.6033; P = 0.6975. 
Abbreviation: AnA, anthranilic acid.
psychiatric  disorders,  eg,  Parkinson’s  disease,35–39 
multiple sclerosis,40 Alzheimer’s disease,41,42 stroke,43 
depression  and  schizophrenia,44,45  and  also  for  the 
treatment of low back pain and as prophylaxis against 
osteoporosis.46,47  The  effectiveness  of  SRT  as  an 
additive treatment for these diseases is significant, but 
the mechanism(s) of action involves many biochemi-
cal events and   further elaboration is necessary. It is 
known that body vibration modifies a wide spectrum 
of bioprocesses, eg, activation of brain neurotrophic Kepplinger et al
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factors, induction of neurotransmitter and hormone 
synthesis  and  release,  stabilization  of  skeletal  and 
muscle activity, and strengthening and recovery of 
balance and posture.9–13
The present study demonstrates for the first time 
that SRT influences tryptophan metabolism in healthy 
human subjects via a moderate but significant lowering 
of serum L-tryptophan, L-kynurenine, and kynurenic 
acid levels. Subjects reported increased stability as 
well as ease in taking steps in the hours following 
SRT. The effect on tryptophan metabolites was time-
dependent, and the reduction was still measurable at 
60 minutes after SRT, indicating a long-lasting effect. 
The  changes  in  L-tryptophan  metabolism  would 
suggest increased incorporation of amino acids into 
ongoing protein synthesis and bone formation, since 
availability of L-tryptophan during bone growth is 
indispensable.48  Enhancement  of  new  bone  forma-
tion due to exercise has been reported in an animal 
  experiment.49 Lowered serum L-tryptophan levels have 
also been reported in rats exposed to exercise.50 Given 
that L-tryptophan crosses the blood-brain barrier in 
significant amounts, changes in serum levels might 
also involve nicotinamide adenine dinucleotide and/
or serotonin synthesis, not only in the periphery, but 
also in the central nervous system.51 The well-being 
reported by subjects after SRT would suggest an anti-
depressant action.39,40,56
The  moderate  reduction  of  L-kynurenine 
induced by SRT was accompanied by lower levels 
of  L-kynurenine  metabolites,  anthranilic  acid,  and 
kynurenic acid. Whereas the reduction of kynurenic 
acid was progressive through to one hour after SRT, 
anthranilic acid levels were normalized. Interestingly, 
treadmill running has been shown to decrease serum 
kynurenic acid levels in rats.14
The  ratio  of  L-kynurenine  to  L-tryptophan  and 
moreover the ratios of anthranilic acid to L-kynurenine 
and kynurenic acid to L-kynurenine were moderately 
altered after SRT, suggesting activation of tryptophan 
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Figure 4. Serum kynurenic acid levels at various time points after stochastic resonance therapy. 
notes: Data represent the mean ± standard error of the mean of 20 independent measurements. *P , 0.05; **P , 0.01 compared with time before 
stochastic resonance therapy. c,f and e,f indicate statistical significance at P , 0.05. a,d; b,c; and b,d indicate statistical significance at P , 0.01. 
a,f and b,f indicate statistical significance at P , 0.001. By one-way analysis of variance, F = 2.1912; P = 0.0601. 
Abbreviation: KYnA, kynurenic acid.Stochastic resonance and tryptophan metabolism
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metabolism after exercise. It is questionable whether 
moderately  activated  kynurenine  metabolism  influ-
ences the activity of the neuronal network and there-
fore has a detectable therapeutic impact. Interestingly, 
the first indication of the therapeutic effect of exercise 
was provided in 1880 by Jean-Martin   Charcot who 
described  using  a  shaking  chair  in  patients  with 
  Parkinson’s  disease,  which  led  to  improvement  of 
symptoms,  in  particular  tremor  and  instability.52 
A  marked  deficit  of  dopaminergic  neurotransmis-
sion and its significance for Parkinson’s symptoms 
was  described  by  Hornykiewicz.53  Interestingly, 
  running activity in an animal model of Parkinson’s 
disease led to improvement of motor symptoms and 
less  degeneration  of  the  dopaminergic  system,54–57 
suggesting a protective effect of movement on dop-
aminergic neurons. Furthermore, in an animal study, it 
was shown that dopamine synthesis and metabolism in 
the striatum increased significantly in rats exposed to 
exercise, and the investigators suggested that physical 
exercise might contribute to adjustment of extracellu-
lar dopamine to within an adequate range.57 Further, 
the therapeutic potential of vibration in patients with 
Parkinson’s  disease  has  been  confirmed  by  many 
investigators.35–37,58 There are also human data show-
ing that exercise transiently increases plasma dop-
amine  levels  in  healthy  stressed  subjects.59–61  Our 
present  findings  make  it  reasonable  to  question  if 
SRT-induced lowering of tryptophan levels and the 
accompanying  reduction  of  plasma  kynurenic  acid 
levels  might  also  involve  enhancement  of  plasma 
dopamine levels,59–61 which could be important for 
restoration of normal biochemical events and have 
a therapeutic effect, not only in the periphery, but 
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Figure 5. Serum L-kynurenine to L-tryptophan ratio at various time points after stochastic resonance therapy. 
notes:  The  data  represent  the  mean  ±  standard  error  of  the  mean  of  20  independent  measurements.  By  one-way  analysis  of  variance, 
F = 0.2906; P = 0.9173. 
Abbreviation: L-KYn/TRP, ratio of L-kynurenine to L-tryptophan.Kepplinger et al
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likely also in the central nervous system. Endogenous 
kynurenic acid has been shown to control extracellu-
lar levels of dopamine in the rat striatum in an in vivo 
study.62 Furthermore, the significance of a tryptophan 
diet and the interaction between increased kynurenic 
acid and lower dopamine levels in the striatum has 
been demonstrated recently.63
There  are  also  human  data  demonstrating 
discrepancies with respect to neurochemical changes 
after exercise, and that whole body vibration leads to 
a moderate increase in cortical dopamine as well as a 
lowering in the striatum and an increase of tryptophan 
in  serum  after  exercise.64  These  discrepancies  are 
probably due to the use of different kinds of exercise 
(running versus sinusoidal vibration versus stochastic 
vibration), different parameters (frequency, amplitude, 
time),  and  vibrational  characteristics  (whole  body 
versus local), and are a reason to study further the 
value of exercise in therapeutic management.
The marked deficit of dopaminergic neurotrans-
mission in Parkinson’s disease53 is partially addressed 
by  levodopa  therapy.65  Interestingly,  a  comparison 
between  levodopa  treatment  and  physical    exercise 
in patients with spinal cord injury revealed a similar 
positive effect for both types of treatment,66 indicating 
enhanced  dopamine  function  during    exercise. 
  Consistent  with  this  research,  use  of    exercise  in 
patients  with  Parkinson’s  disease  significantly 
increased  the  therapeutic  efficacy  of  levodopa.67 
Although the improvement in Parkinsonian symptoms 
after SRT is transient, the positive effect would nev-
ertheless confirm an advantage of SRT and suggests 
that it has therapeutic value in the rehabilitation pro-
cess. Importantly, the combination of levodopa ther-
apy and SRT might enable a decrease in the levodopa 
dose, thereby reducing the side effect of dyskinesia.
Increased  dopamine  levels  in  rat  and  human 
plasma  due  to  physical  exercise  have  also  been 
described by Yoshizumi et al,68 who suggested that 
the dopamine increase is not only due to increased 
release from the sympathoadrenal system, but also 
to  accelerated  conversion  of  sulfoconjugated  cat-
echolamines in plasma. The activity of phenol sulfo-
transferase, an enzyme which conjugates dopamine, 
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Figure 6. Serum anthranilic acid/L-kynurenine ratio at various time points after stochastic resonance therapy. 
notes: The data represent the mean ± standard error of the mean of 20 independent measurements. *P , 0.05 compared with time before stochastic 
resonance therapy. a,f; b,d; and c,d: indicates statistical significance at P , 0.05. d,e indicates statistical significance at P , 0.01. d,f indicates statistical 
significance at P , 0.001. By one-way analysis of variance, F = 0.5689; P = 0.7237. 
Abbreviation: AnA/L-KYn, anthranilic acid/L-kynurenine.Stochastic resonance and tryptophan metabolism
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varies  widely  among  different  species  and  within 
various organs, but shows highest activity in the rat 
liver.69 In the normal aged human brain, the highest 
activity of phenol sulfotransferase was reported in 
the cortical regions and limbic structures, while the 
lowest was found in the basal ganglia regions.70 Inter-
estingly, in Parkinson’s disease, a marked increase 
in phenol sulfotransferase activity has been seen in 
the caudate nucleus, whereas in other brain regions, 
particularly in the hypothalamus and cortical brain 
regions, it was reduced.70 Given that conjugated dop-
amine is decreased after exercise while free dopamine 
is increased,68 it is unclear whether the therapeutic 
effect of exercise and SRT in Parkinson’s patients is 
also in part due to deconjugation of sulfoconjugated 
dopamine  in  the  caudate  nucleus.  The  kynurenine 
aminotransferases  responsible  for  kynurenic  acid 
synthesis are widely distributed throughout the mam-
malian body, particularly in the liver.19–21 Increased 
kynurenine aminotransferase activity in the striatum 
has been found in patients with Alzheimer’s disease 
and in those with Parkinson’s disease.30 Interestingly, 
kynurenic  acid  has  an  inhibitory  effect  on  several 
human recombinant sulfotransferases.71 The effect is 
very moderate, with the IC50 for kynurenic acid being 
in the micromolar range in experimental conditions, 
and the physiological mechanisms for this are not as 
yet clear.
The decrease in kynurenic acid levels after SRT 
might  involve  activation  of  glia-depressing  factor, 
recently proposed by Baran et al.72 Glia-depressing 
factor has the ability to block kynurenine aminotrans-
ferase and probably simultaneously blocks glial activ-
ity, thereby exerting a direct or indirect neurotrophic 
effect. In multiple sclerosis, glia-depressing factor is 
reduced72 while kynurenic acid is increased,73 and use 
of SRT in patients with multiple sclerosis improved 
their  clinical  status  significantly.40 Amelioration  of 
some pain conditions has also been reported after use 
of SRT.46,47
Summary
SRT offers a new opportunity to influence tryptophan 
metabolism along the kynurenine pathway. Our data 
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add to the body of evidence showing the importance of 
SRT, and indicate that exercise is a useful method for 
balancing biochemical and physiological processes in 
the body. Furthermore, SRT can be very useful in the 
repair of biochemical processes in pathological con-
ditions,  including  motor  impairment,  dementia,  and 
chronic low back pain, as well as improving well-being. 
In the near future, it would be necessary to identify the 
duration of efficiency of SRT in respect to changes in 
tryptophan metabolism and, furthermore, to confirm 
the  proposed  mechanism(s)  of  interaction  between 
kynurenic acid and the dopaminergic system in patients 
with disease and in healthy control subjects.
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